More on McKesson (MCK): FQ3 misses on the bottom line while beating total sales estimates, driven by higher medical-surgical distribution and services revenues. For FY13, EPS estimates are guided lower, now expected to be between $7.15 - 7.35 to $7.10 - 7.30 per share. Street estimates are for an EPS of $7.30. The company also says it's board has authorized an additional $500M to its stock buyback program. Shares -2.6% AH.